NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
... Pharma for Pylera (R) , an innovative 3-in-1 capsule
therapy for the eradication of Helicobacter ... over the last ten years, is a patented 3-in-1 capsule
therapy. Each Pylera (R) capsule
contains bismuth subcitrate potassium, ...
New Report Just Published: World Endoscopy Systems Market Report
... Suites II-2
Confocal Microendoscopes II-3
High Definition Endoscopy ... (includes corresponding
Table 4: Leading Players in the Global capsule
Market (2008E): Percentage ...
BMP Sunstone Acquires 'Runchang Capsule' and Related LFHC Technology
... acquire "Runchang capsule," a liquid-
filled hard capsule
(LFHC) used to treat constipation. Sunstone will ... The Company plans to start
promoting the Runchang capsule
in the Chinese market in late 2009.
Zhiqiang ... Officer of BMP Sunstone,
commented, "The Runchang capsule
is a natural plant-based medicine for ...
NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
... capsules in 2007, giving it a 50% share of
market. Its experience, expertise and ... and encapsulation due to its leading edge capsule
technology and formulation ... innovation. As the leading
global gelatin capsule
manufacturer, Capsugel is the most ...
FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
... agreement to develop
products using a novel capsule
technology developed by FMC. The
technology is expected to significantly ... trials in early 2009 and launch of the
is expected in 2010-2011.
FMC's novel ...
AOBO Announces New Product Launch
... Boke Nasal Spray Brand -
- Diversifies Product Offering with capsule
American Oriental Bioengineering, Inc. (NYSE: AOB ... network, and
the strength of the Boke brand, we believe that the Jingwei capsule
become one of AOBO's leading products over time. We are confident ...
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
... PhD., remarked, "These
results demonstrate that Oramed's oral insulin capsule
had a good safety
profile and was effective on patients with type 1 ... through its
patented flagship product, an orally ingestible insulin capsule
phase 2 clinical trials. Established in 2006, Oramed's ...
Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009
... formulation of this antihypertensive is the world's first in capsule
form, making it easier to swallow. Sales of more than 500,000 capsules are ... including lower cost of active pharmaceutical ingredients (API), the capsule
formulation, greater efficacy and reduced side effects.
Sales of ...
NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance
... oral capsules, which is widely recognized as the
world leader in capsule
Staffan Stromberg, Vice President of Technical ... have signed these contracts with global leaders in
high capacity API and capsule
production. We project these agreements should
cover the high sales ...
Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
... ANDA with the FDA containing a Paragraph IV
certification for the 8 mg eq. capsule
strength of Razadyne ER on March 1,
2006. Barr amended its ANDA on March 10, 2006 to include the 16 mg eq. and
24 mg eq. capsule
strengths in its filing. Following receipt of the notice
from the FDA that ...
FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
... courses of moderately emetogenic
chemotherapy. A single 0.5 mg ALOXI capsule
is administered approximately
one hour prior to the start of ... and repeat courses of moderately emetogenic chemotherapy. One ALOXI
0.5 mg capsule
is administered approximately one hour prior to the start ...
China Kangtai Cactus Biotech Announces Record Second Quarter Results
... products such as Cactus Protein Nutrient,
Cactus Calcium Peptide Soft capsule
and Cactus Shuxin capsule
customers and expanded distribution.
Gross profit for the ...
Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
... U.S. patent infringement litigation pertaining to Impax's proposed
formulation of Wyeth's EFFEXOR XR(R) antidepressant have
been approved by ... Wyeth has granted Impax a license
that would permit Impax to launch its capsule
formulation of Effexor XR on
or after June 1, 2011, subject to earlier ...
Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
... risk that regulatory authorities may find our
resubmission of the indiplon capsule
NDA incomplete or insufficient or
otherwise unapprovable or that approval ... a marketing partner on reasonable terms or at all; risk that the
labeling granted by regulatory authorities may limit the
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
... via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at ...
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
... quarter of 2009.
DR Cysteamine is Raptor's proprietary enteric-coated micro-bead formulation of cysteamine bitartrate contained in a gelatin capsule
and designed for increased absorption, less frequent dosing and improved tolerability relative to the current standard of care. Published studies ...
Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
... The Mercury Project targets counties within 31
provinces in the PRC to promote our 'Gan Wang' Compound, our Paracetamol and
Amantadine Hydrochloride capsule
-- an over-the-counter drug for the treatment
of influenza. As with hepatitis, influenza affects a large portion of the
population in the People's ...
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
... June 1, 2009, 3:30-3:45 PM
About CCX282-B (Traficet-EN)
Traficet-EN is an orally-available small molecule drug which is administered in capsule
form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 ...
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
... AEROLIZER should not be used to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Do not use more than one capsule
twice daily. FORADIL AEROLIZER should be used with caution in patients with cardiovascular disorders. FORADIL AEROLIZER is not a substitute for ...
Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril
... with significant competitive advantages, including lower cost active pharmaceutical ingredients (API), and being the first in the world to offer capsule
formulation, which is not only easier to swallow, but also has greater efficacy and reduced side effects compared to earlier versions of the drug. ...
American Oriental Bioengineering Reports First Quarter 2009 Financial Results
... of 2009, roughly
flat to the prior year period, reflecting continued demand for Boke nasal
spray and Jinji Yimucao products and a shift of Jinji capsule
OTC to prescription sales. Nutraceutical products generated revenue of
approximately $8.9 million in the first quarter of 2009, up ...
Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
... in 5-15% of subjects in clinical studies with Durezol included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule
opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% ...
The Elmasonic S Ultrasonic Cleaner: Designed for the Scientific Laboratory
... labs, in particular, can employ large Elmasonic S baths to clean stainless steel, Delrin®, and Teflon® plastic parts from tablet and capsule
manufacturing equipment between batches. In addition to cleaning validation, The Elmasonic S units are used by drug companies for solvent degassing ...
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
... & Renshaw Conference will give Oramed an important platform
to present the accomplishments we have achieved in our development of an
oral insulin capsule
and our unique position as a technology pioneer in the
field of oral delivery solutions," said Kidron.
For more information about Rodman & Renshaw ...
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
... in dactylitis, though the changes were not statistically
significant with the 50 mg dose. Enthesitis, an inflammation of a tendon,
ligament or joint capsule
insertion to the bone, and dactylitis, a swelling
of digits in the hands or feet, are estimated to affect more than one-third
of people with ...
Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
... morning at the Modern Mucosal
Vaccines, Adjuvants & Microbicides (MMVAM) international conference in
Delivery of flu vaccine via a capsule
rather than an injection offers
critical advantages, particularly in the case of a pandemic. The Vaxart
vaccine formulation can withstand ambient ...
Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
In a double-blind, placebo-controlled, FDA-approved human trial, 40 Type 2 diabetics consumed three time a day (before each meal) a capsule
containing either 250 mg of Emulin™ or a placebo. Participants were divided into four sub-groups: placebo only; placebo and metformin, a ...
Beaumont Doctor's Invention Improves Cataract Surgery Outcomes
... eyeball behind the lens, can move into the front of the eye when the
lens is not fully supported. This movement can lead to complications such
tears, zonular dialysis, and dislocation of the lens into the
back of the eye, requiring the patient to have an additional surgery by a
Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more
... will paint the inside walls of this chamber, heating the metal walls and causing them to emit X-rays that will fill the can, bombard a small plastic capsule
in the can's center, implode the capsule, and trigger the fusion of tritium and deuterium inside.
Lead researcher Christopher A. Haynam with LLNL ...
New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone)
candidates to King Pharmaceuticals in November 2005.
ORADUR is a proprietary technology designed to transform short-acting
dosage forms into sustained release oral products, with the
added benefit of being less prone to abuse than other controlled release
dosage forms on ...
China Medicine Announces Solid First Quarter 2008 Results
... for a
number of products before year end.
The Company is also on track to complete the documentation for
laboratory trial results for Yutian capsule
for the treatment of chronic
obstructive pulmonary disease, and plans to submit them for approval by the
State Food and Drug Administration in June ...
Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule
... focused on the
development of oral delivery solutions based on proprietary technology.
Oramed is currently developing an orally ingestible insulin capsule
treatment of diabetes. The oral administration of insulin is more
physiological than the current delivery method, mimicking the natural ...
Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
... monoclonal antibodies will not lead to the
development of bacterial resistance. The target of the antibody is a
carbohydrate on the bacterial capsule
known as PNAG. PNAG has been found to
be a critical factor in the virulence and immune response to MRSA as well
as non-MRSA staphylococcal infections ...
Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
... -- Today, Ganeden Biotech
announced that Sustenex(TM), its all-natural daily probiotic supplement is
now available nationwide. Each Sustenex(TM) capsule
contains at least 2
billion live probiotic cells of GanedenBC30, a proprietary, patented strain
of Bacillus coagulans designed to help promote immune ...
Arpida Announces Full Year 2007 Financial Results
... of a Phase I study with oral
iclaprim. The primary aim of the study was to assess the safety and
tolerability of single ascending doses of an oral capsule
iclaprim in healthy volunteers.
Early in 2008, Arpida announced that it had received authorisation from
the U.S. FDA to conduct a ...
BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
... trial in patients with cutaneous t-cell lymphoma In October, BioCryst began enrolling patients in a pivotal, multinational trial of an oral capsule
formulation of its lead oncology drug candidate, forodesine HCl for cutaneous t-cell lymphoma (CTCL). As presented at the 2007 American ...
China Shenghuo to Market 12Ways(R) Skin Care Products in the U.S. through Agreement with Home Shopping Group
... sales expansion if the campaign is successful. The products will be
sold as a skin care kit including moisturizer, toner, skin care mask,
lotion and capsule
taken to improve internal health.
"We are very pleased to partner with HSG to sell 12Ways, marking our
entry into the U.S. market," said Mr. Gui ...
Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
... patients with
complicated Skin and Skin Structure Infections (cSSSI).
The key objective of the study is to assess the clinical efficacy of an
formulation of iclaprim as step-down therapy in comparison
with intravenous (IV) vancomycin in the treatment of cSSSI. The primary
endpoint will be ...
Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
... tissue. This can help reduce
the risk of disease recurrence and facilitate follow-up monitoring.
In remnant ablation, patients take a drink or a capsule
radioactive iodine, which is taken up by any remaining thyroid cells. To
enhance the uptake of radioiodine, the level of thyroid ...
Neurocrine Announces Work Force Restructuring
... include, but are not limited to; risk
that the Company will not be able to address issues and or requests set
forth in the December 12, 2007 indiplon capsule
action letter from the FDA
in a timely manner if at all; risk that the Company will not be able to
address issues and or requests set forth in the ...